Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Chesnel

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Neural Regeneration Research|December 12, 2024
LPAR3: a shared target for neurodegenerative diseases?Susan Acton, Laurent Chesnel
Journal of Global Antimicrobial Resistance|July 11, 2017
In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agentsCédric Jacqueline, Karen Howland, Laurent Chesnel
The Journal of Biological Chemistry|November 24, 2005
Pneumococcal beta-lactam resistance due to a conformational change in penicillin-binding protein 2xRaphaël Carapito, Laurent Chesnel, Thierry Vernet, et al.
Molecular Microbiology|April 28, 2005
A yeast genetic system for the identification and characterization of substrate proteins transferred into host cells by the Legionella pneumophila Dot/Icm systemEva M Campodonico, Laurent Chesnel, Craig R Roy
Journal of Industrial Microbiology & Biotechnology|December 17, 2015
Discovery and development of surotomycin for the treatment of Clostridium difficileVictoria Knight-Connoni, Carmela Mascio, Laurent Chesnel, et al.
European Journal of Biochemistry|March 16, 2002
Increase of the deacylation rate of PBP2x from Streptococcus pneumoniae by single point mutations mimicking the class A beta-lactamasesLaurent Chesnel, André Zapun, Nicolas Mouz, et al.
Antimicrobial Agents and Chemotherapy|May 7, 2014
Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faeciumCarmela T M Mascio, Laurent Chesnel, Grace Thorne, et al.
Antimicrobial Agents and Chemotherapy|May 6, 2015
Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus speciesHannah M Adams, Xiang Li, Carmela Mascio, et al.
Journal of Clinical Microbiology|December 18, 2015
Impact of Variations in Test Method Parameters on In Vitro Activity of Surotomycin against Clostridium difficile and Surotomycin Quality Control Limits for Broth Microdilution and Agar Dilution Susceptibility TestingMaria M Traczewski, Jennifer Deane, Daniel Sahm, et al.
Antimicrobial Agents and Chemotherapy|June 10, 2015
Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficileMohammed Zahidul Alam, Xiaoqian Wu, Carmela Mascio, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Neural Regeneration Research|December 12, 2024
LPAR3: a shared target for neurodegenerative diseases?Susan Acton, Laurent Chesnel
Journal of Global Antimicrobial Resistance|July 11, 2017
In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agentsCédric Jacqueline, Karen Howland, Laurent Chesnel
The Journal of Biological Chemistry|November 24, 2005
Pneumococcal beta-lactam resistance due to a conformational change in penicillin-binding protein 2xRaphaël Carapito, Laurent Chesnel, Thierry Vernet, et al.
Molecular Microbiology|April 28, 2005
A yeast genetic system for the identification and characterization of substrate proteins transferred into host cells by the Legionella pneumophila Dot/Icm systemEva M Campodonico, Laurent Chesnel, Craig R Roy
Journal of Industrial Microbiology & Biotechnology|December 17, 2015
Discovery and development of surotomycin for the treatment of Clostridium difficileVictoria Knight-Connoni, Carmela Mascio, Laurent Chesnel, et al.
European Journal of Biochemistry|March 16, 2002
Increase of the deacylation rate of PBP2x from Streptococcus pneumoniae by single point mutations mimicking the class A beta-lactamasesLaurent Chesnel, André Zapun, Nicolas Mouz, et al.
Antimicrobial Agents and Chemotherapy|May 7, 2014
Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faeciumCarmela T M Mascio, Laurent Chesnel, Grace Thorne, et al.
Antimicrobial Agents and Chemotherapy|May 6, 2015
Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus speciesHannah M Adams, Xiang Li, Carmela Mascio, et al.
Journal of Clinical Microbiology|December 18, 2015
Impact of Variations in Test Method Parameters on In Vitro Activity of Surotomycin against Clostridium difficile and Surotomycin Quality Control Limits for Broth Microdilution and Agar Dilution Susceptibility TestingMaria M Traczewski, Jennifer Deane, Daniel Sahm, et al.
Antimicrobial Agents and Chemotherapy|June 10, 2015
Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficileMohammed Zahidul Alam, Xiaoqian Wu, Carmela Mascio, et al.
Pageof 4